Extended Data Fig. 3: Intracerebroventricular GDF11 infusion recapitulates all aspects of systemic treatment except neurogenesis.
(a) Schematic representation of the experimental procedure: miniosmotic pumps were implanted in the lateral ventricle and rGDF11 or vehicle was infused at a constant rate over 2 weeks. (b) Measurement of discrimination index during the NORT (percentage of time spent to observe the novel object divided by the percentage of total investigation time for both objects) (n = 4 mice per group). (c) Measurement of grooming frequency during the Splash test (n = 5 mice per group). (d) Measurement of time spent in the Light box during the Light/Dark Box Test (n = 6 mice per group). (e) Representation of latency to eat for mice during the Novelty Suppressed feeding test (n = 5 mice per group). (f) Quantification of Sox2+ NSCs in the SGL of the dentate gyrus (nVeh = 4 mice, nGDF11 = 5 mice). (g) Quantification of DCX+ neuroblasts in the SGL of the dentate gyrus (nVeh = 4 mice, nGDF11 = 5 mice). (h–k) Quantification of Western blots by optical density for Beclin 1 (i) (nVeh = 4 mice, nGDF11 = 5 mice), Atg5 (j) (nVeh = 4 mice, nGDF11 = 5 mice), and Lamp1 (k) (nVeh = 4 mice, nGDF11 = 5 mice). Two-sided Mann–Whitney test for two-group comparisons; P values < 0.05 are represented on the graph; mean ± s.e.m.
